# Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

Source: https://onco.cc/trials/nct07736937/  
OnCo record `nct07736937` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TUB-040 + Carbo + BEV in ovarian cancer, run by Tubulis GmbH, now recruiting.

## Summary

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer is a phase 1/2 interventional study registered as NCT07736937 by Tubulis GmbH, with 72 participants planned, started 2026-03-30 and due to reach its primary completion in 2028-03. Interventions recorded: TUB-040 + Carbo + BEV.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07736937
- Phase: 1/2
- Setting: A Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of TUB-040, in Combination With Standard Ovarian Cancer Drugs in Patients With High-grade Epithelial Serous or Endometrioid Epithelial Ovarian Cancer OC)
- Sponsor: Tubulis GmbH
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT07736937: https://clinicaltrials.gov/study/NCT07736937

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Tubulis (Gilead)](https://onco.cc/companies/tubulis/)

---
JSON: https://onco.cc/api/v1/entities/nct07736937.json